Breakthrough Data of DPX-Survivac immunotherapy in Patients with Advanced Recurrent Ovarian Cancer

Published on February 26, 2020 Background In heavily pretreated patients, for whom there remains a tremendous unmet need with limited options beyond single-agent chemotherapy, which generates responses in just 12%…

Continue ReadingBreakthrough Data of DPX-Survivac immunotherapy in Patients with Advanced Recurrent Ovarian Cancer